Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome
ACS Medicinal Chemistry Letters August 15, 2025 DOI: 10.1021/acsmedchemlett.5c00475 via OpenAlex
Summary
AI-generated from the abstractCertain novel compounds, including psilocybin, show promise for treating psychiatric conditions through unique pharmacological actions. By modifying their chemical structure, researchers can achieve functional selectivity at serotonin (5-HT) receptors, reducing hallucinogenic effects while maintaining therapeutic benefits. The work combines receptor-level and behavioral evidence to support these compounds as rational treatments for demoralization syndrome and depression-related disorders.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Agonism Hallucinogen Divergence linguistics 5-HT Receptor |
| Key finding | Structural modifications of phenalkylamines and tryptamines can yield functional selectivity at 5-HT receptors, reducing hallucinogenic risk while preserving therapeutic efficacy for demoralization syndrome and depression-related conditions. |
Abstract
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as rational therapeutics for demoralization syndrome and depression-related conditions.